Anastasiya Shor headshot

Anastasiya Shor, Pharm.D., BCPS

Assistant Professor

Director of the Drug Information Center

Department of Pharmacy Practice

Touro College of Pharmacy

Areas of Expertise

Drug Information

Biography

Anastasiya Shor began her pharmacy career at a health economics and outcomes research start-up, where she compiled and transformed clinical, quality of life, and economic evidence into materials for health care providers and clients in the pharmaceutical industry. She has since worked as a community pharmacist, investigational pharmacist, and a nutrition support pharmacist. Her favorite professional activities include drug information, content development, and content delivery; she also enjoys working with students, assisting with professional growth, and providing mentorship. Dr. Shor continues to advance the profession of pharmacy by promoting scholastic achievement, provider status, and leadership.

Education

  • Lasdon Research Fellowship Program in Drug Information and Medical Communications, LIU Pharmacy and Medical Knowledge Group, NY, 2019-2020
    LIU Pharmacy, PharmD, NY, 2016

Honors and Awards

  • Phi Lambda Sigma Pharmacy Leadership Society
  • Alpha Chi Honor Society
  • Alpha Lambda Delta Honor Society
  • Who’s Who Among Students in American Universities and Colleges
  • LIU First Place Winner, APhA-ASP Local Patient Counseling Competition
  • Stephen M. Gross Faculty Council Award
  • Distinction in Honors Award
  • Paula M. Cooper Award
  • Crystal Blackbird - Distinguished President Award
  • Recipient of APhA-ASP Senior Recognition Certificate
  • Recipient of Graduate Excellence Scholarship
  • Recipient of the Malvina, Leo, and Stephen Jochsberger Endowed Scholarship
  • Recipient of Win Gerson Marketing and Communications Endowed Scholarship
  • Dean’s list for academic excellence

Recent Publications

Shor A, Forsythe A, Li S, Galaznik A. Systematic literature review (SLR) of health state utility values (HSUV) in epidermal growth factor receptor mutant (EGFR-Mutant) non-small cell lung cancer (NSCLC) patients previously treated with targeted therapies. Value Health. 2018;21: S35-S36. doi: 10.1016/j.jval.2018.04.300

Shor A, Forsythe A, Li S, Galaznik A. Comparative effectiveness of treatments in epidermal growth factor receptor mutant (EGFR-mutant) non-small cell lung cancer (NSCLC) patients who failed on prior targeted therapies: a systematic literature review (SLR). Value Health. 2018;21: S16. doi: 10.1016/j.jval.2018.04.096

Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G. Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer? Cancer Manag Res. 2018; 10:1015-1025. doi:10.2147/CMAR.S162714

Tremblay G, Arondekar B, Chan G, Shor A, Forsythe A, Yun S. Covariate adjusted indirect treatment comparison (ITC) of glasdegib plus low dose Ara-C versus a hypomethylating agent for acute myeloid leukemia patients ineligible for intensive chemotherapy. Blood. 2017;130(Suppl 1):5665

Tremblay G, Meier G, Copher R, Misurski D, Pan J, Baig M, Tamai T, Kraljevic S, Shor A, Forsythe A. Network meta-analysis of treatments for unresectable hepatocellular carcinoma. Value Health. 2017;20(9): A414. doi: 10.1016/j.jval.2017.08.096

Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G. 262P PFS/TTP as a potential surrogate for OS in HR+, HER2– MBC. Ann Oncol. 2017;28(suppl_5): v84-v85. doi:10.1093/annonc/mdx365.025

Klang M, Shor A, Abramova I. Lidocaine-epinephrine-bicarbonate stability. InPHARMation Pharmacy Newsletter, Memorial Sloan Kettering Cancer Center. 2015:9(9); 3

Recent Presentations

Shor A, Nathan JP, Grossman S, Kudadjie-Gyamfi E. F-238: Comfort with and Knowledge of Medical Cannabis: a Study of Pharmacists at a Continuing Education Program in New York. Presented at the 55th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, Virtual. December 6-10, 2020

Forsythe A, Schneider J, Shor A, Patel P, Briggs A. PCN261 Application of Oncology Value Frameworks to the 2nd line Treatments in Renal Cell Carcinoma (2L-RCC). Presented at the 22nd International Society for Pharmacoeconomics and Outcomes Research Annual International Congress, Boston, MA. May 20-24, 2017

Klang M, Shor A, Abramova I. Lidocaine and bupivacaine syringe stability study. Presented at the 50th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, New Orleans, LA. December 6-10, 2015

Professional Service

  • Faculty Advisor, Drug Information Association
  • Alumni Board Member, LIU Pharmacy
  • President, Phi Delta Chi New York Alumni Chapter
  • New Practitioner Mentor, American Pharmacists Association- Academy of Student Pharmacists (APhA-ASP)
  • Medical Mission Trip, International Medical Relief, Manaus, Brazil

Memberships and Affiliations

  • New York Council of Health-System Pharmacists
  • Phi Lambda Sigma Pharmacy Leadership Society
  • Phi Delta Chi Professional Pharmacy Fraternity

Languages

English, Russian, Spanish, Ukrainian

Hobbies

  • Watercolor painting, outdoor activities, cooking